HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Anthralin (Dithranol)

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

Also Known As:

Dithranol; Micanol; 1,8,9-Anthracenetriol; 1,8-Dihydroxy-9(10H)-anthracenone; Anthraforte; Anthranol; Bioglan Brand of Anthralin; Cahill May Roberts Brand of Anthralin; Cignolin; Cygnoline; Dermal Brand of Anthralin; Dihydroxyanthranol; Dithrocream; Ditranol FNA; FNA Brand of Anthralin; Hamilton Brand of Anthralin; Lasan; Psoradrate; Psoricrème; Schering-Plough Brand of Anthralin; Stiefel Brand 1 of Anthralin; Stiefel Brand 2 of Anthralin; Vinas Brand of Anthralin; 1,8 Dihydroxy 9 anthrone; Schering Plough Brand of Anthralin; 1,8-Dihydroxy-9-anthrone

Networked: 482 relevant articles (66 outcomes, 67 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	van de Kerkhof, P C M: 11 articles (02/2014 - 04/2002)
2.	Prins, M: 9 articles (05/2004 - 09/2000)
3.	van der Valk, P G M: 8 articles (02/2008 - 04/2002)
4.	Swinkels, O Q J: 7 articles (10/2006 - 04/2002)
5.	Gerritsen, M J P: 6 articles (05/2004 - 04/2002)
6.	Kucharekova, M: 4 articles (10/2006 - 04/2002)
7.	de Jong, E M G J: 3 articles (02/2014 - 01/2010)
8.	Seyger, M M B: 3 articles (02/2014 - 01/2010)
9.	Kaur, Inderjeet: 3 articles (07/2010 - 08/2002)
10.	Quehenberger, Franz: 2 articles (11/2015 - 11/2015)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 11/01/2015 - "Despite the known limitations of CID, this survey indicates that dithranol remains a highly efficacious and valuable treatment option as induction therapy in psoriasis. " 11/01/2015 - "Despite the known limitations of CID, this survey indicates that dithranol remains a highly efficacious and valuable treatment option as induction therapy in psoriasis. " 01/01/2001 - "Dithranol is highly effective in the treatment of psoriasis, however its mode of action is still not well known. " 01/01/2000 - "For UVB, the most effective wavelength in clearing psoriatic lesions was found to be of 313 nm. The efficacy of whole body exposure to narrow-band UVB (311 nm) combined with dithranol in psoriasis has not been evaluated to date. " 08/01/1998 - "Anthralin is the most common therapeutic agent among a small number of pro-oxidant, 9-anthrones effective in the topical treatment of psoriasis. "
2.	Erythema 12/01/2009 - "We evaluated 21 psoriatic lesions (plaques, patches and pinpoint lesions) including 4 lesions in remission with anthralin induced erythema and 4 controls of healthy, uninvolved skin. " 06/01/1995 - "The study showed conclusively that TEWL was not affected by the application of dithranol, even though pronounced erythema occurred." 02/01/1987 - "These findings may explain why the addition of tar minimizes dithranol-induced erythema, as reported in clinical studies. " 08/01/1981 - "Pharmacological studies of anthralin erythema." 09/01/1999 - "We felt that if the minimal erythema concentration (MEC) of anthralin could be determined initially in an individual, this ought to be near or at the final achievable therapeutic concentration. "
3.	Inflammation 01/01/2003 - "The expression of epidermal proliferation, differentiation and inflammation markers and the clinical irritation scores indicate that the application of a high potency corticosteroid (CP) is the best approach to minimise dithranol irritation, whereas CTS had virtually no effect on dithranol irritation during this 4-day experimental model." 11/01/2002 - "The present study aims to analyse the effect of single and repeated applications of dithranol on aspects of epidermal proliferation, keratinisation and inflammation in the psoriatic plaque. " 09/01/1996 - "The present study suggests that Micanol predominantly had diminishing effects on inflammation markers, hardly affecting the epidermis. " 01/01/1992 - "This study shows that H1-receptor blockade does not inhibit anthralin inflammation." 07/01/1990 - "This study shows that anthralin-induced inflammation and its therapeutic effect can be dissociated."
4.	Alopecia Areata 01/01/2004 - "Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin." 11/01/1987 - "Compared with other currently available topical treatments, anthralin appears to be a reasonable therapeutic option for severe alopecia areata." 11/01/1987 - "Anthralin cream 0.5% to 1.0% was used to treat 68 patients with severe alopecia areata. " 11/01/1987 - "Evaluation of anthralin in the treatment of alopecia areata." 11/01/1985 - "Anthralin therapy for alopecia areata."
5.	Warts (Wart) 01/01/1984 - "In order to investigate the efficacy of anthralin ( Anthraderm ) in the treatment of warts a randomized controlled trial was carried out in 72 patients. " 01/01/1986 - "Thirty patients having mosaic warts of the soles for 2 years (range 3 months-6 years) were treated daily with a wax-based anthralin stick supplemented by weekly paring. " 01/01/1986 - "Anthralin stick (Anthraderm) in the treatment of mosaic warts." 01/01/1984 - "Anthralin 2% ( Anthraderm ) was found to have a significantly better effect, especially in the group of patients with warts solely on the hands." 01/01/1984 - "Wart treatment with anthralin."

Related Drugs and Biologics

1.	Anthralin (Dithranol)
2.	calcipotriene (calcipotriol)
3.	Retinoids
4.	Adrenal Cortex Hormones (Corticosteroids)
5.	Clobetasol (Clobetasol Propionate)
6.	Cyclosporine (Ciclosporin)
7.	Coal Tar (Estar)
8.	Salicylic Acid (2 Hydroxybenzoic Acid)
9.	Vitamin D
10.	Indomethacin (Indometacin)

Related Therapies and Procedures

1.	Phototherapy (Light Therapy)
2.	Photochemotherapy (Photodynamic Therapy)
3.	Day Care (Partial Hospitalization)
4.	PUVA Therapy
5.	Aftercare (After-Treatment)